T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Flowserve
FLS
$10.2B
| $1.19B | 0.25% |
21,152,893
+8,847,863
| +72% | +$513M |
|
102
Cigna
CI
$72.6B
| $1.18B | 0.24% |
9,152,792
+158,913
| +2% | +$18.5M |
|
103
Verizon
VZ
$194B
| $1.18B | 0.24% |
24,300,676
-483,948
| -2% | -$23.4M |
|
104
ServiceNow
NOW
$129B
| $1.16B | 0.24% |
73,522,175
+578,215
| +0.8% | +$8.52M |
|
|
WBA
105
DELISTED
Walgreens Boots Alliance
WBA
| $1.16B | 0.24% |
13,666,732
+2,467,065
| +22% | +$196M |
|
106
AT&T
T
$165B
| $1.16B | 0.24% |
46,917,825
-1,746,409
| -4% | -$44.4M |
|
107
PNC Financial Services
PNC
$102B
| $1.15B | 0.24% |
12,367,303
-487,884
| -4% | -$44M |
|
108
Weyerhaeuser
WY
$17.8B
| $1.15B | 0.24% |
34,718,458
-6,073,625
| -15% | -$213M |
|
109
Philip Morris
PM
$289B
| $1.15B | 0.24% |
15,275,676
-1,570,154
| -9% | -$127M |
|
110
Comcast
CMCSA
$89.2B
| $1.14B | 0.23% |
40,233,558
+5,682,930
| +16% | +$163M |
|
111
International Paper
IP
$21.9B
| $1.12B | 0.23% |
21,333,362
-765,162
| -3% | -$39.7M |
|
112
AES
AES
$10.5B
| $1.11B | 0.23% |
86,411,891
+20,997,888
| +32% | +$263M |
|
113
Exelon
EXC
$46.3B
| $1.1B | 0.23% |
45,898,903
+3,881,081
| +9% | +$96.1M |
|
|
TWX
114
DELISTED
Time Warner Inc
TWX
| $1.09B | 0.23% |
12,900,480
-665,962
| -5% | -$55.3M |
|
115
AbbVie
ABBV
$439B
| $1.09B | 0.22% |
18,567,376
+2,774,585
| +18% | +$168M |
|
116
Northern Trust
NTRS
$34.9B
| $1.03B | 0.21% |
14,719,923
-602,458
| -4% | -$41.1M |
|
117
BioMarin Pharmaceuticals
BMRN
$13.7B
| $1.02B | 0.21% |
8,174,589
+6,235,807
| +322% | +$661M |
|
118
Nike
NKE
$60.4B
| $1.01B | 0.21% |
20,202,946
+1,740,104
| +9% | +$83.2M |
|
119
NiSource
NI
$20.2B
| $1.01B | 0.21% |
58,151,967
+2,182,515
| +4% | +$37M |
|
120
JB Hunt Transport Services
JBHT
$25.7B
| $1.01B | 0.21% |
11,768,990
-2,956,730
| -20% | -$247M |
|
|
AET
121
DELISTED
Aetna Inc
AET
| $997M | 0.21% |
9,358,923
+159,470
| +2% | +$15.6M |
|
122
Simon Property Group
SPG
$71.3B
| $996M | 0.21% |
5,089,303
-88,141
| -2% | -$17.1M |
|
123
Hilton Worldwide
HLT
$72.7B
| $988M | 0.2% |
11,121,507
+1,875,822
| +20% | +$155M |
|
124
Alkermes
ALKS
$8.44B
| $985M | 0.2% |
16,160,128
-23,940
| -0.1% | -$1.64M |
|
125
Celanese
CE
$4.78B
| $981M | 0.2% |
17,559,889
+312,490
| +2% | +$17.7M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.